Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

In early April, President Donald Trump gathered dozens of hard-hat-clad coal miners around him in the White House East Room.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Innovent announces phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) published in the NEJM: San Francisco, US Tuesday, May 27, 2025, 11:00 Hrs [IST ...

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

GLORY-3: A Phase 3 trial comparing mazdutide and semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial ...

Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three ...

Zydus Lifesciences is targeting double-digit revenue growth for the fiscal year 2026, driven by robust performance in its ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.